TD Asset Management Inc. increased its stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX – Get a rating) by 3.0% in the 1st quarter, according to its last filing with the Securities & Exchange Commission. The fund held 49,897 shares of the company after buying an additional 1,435 shares during the quarter. TD Asset Management Inc. owned approximately 0.06% of IDEXX Laboratories worth $27,297,000 when it last filed with the SEC.
Other hedge funds and other institutional investors have also recently changed their holdings in the company. Riverview Trust Co bought a new stock position in IDEXX Laboratories in Q1 worth about $27,000. Sageworth Trust Co of South Dakota acquired a new position in IDEXX Laboratories in Q4 worth approximately $47,000. City State Bank acquired a new position in IDEXX Laboratories in Q4 worth approximately $42,000. Confluence Wealth Services Inc. acquired a new position in IDEXX Laboratories in Q4 worth approximately $61,000. Finally, O Dell Group LLC acquired a new position in IDEXX Laboratories in Q1 worth approximately $62,000. 84.92% of the shares are held by hedge funds and other institutional investors.
Changes to analyst ratings
Several equity analysts have recently weighed in on IDXX shares. Morgan Stanley cut its price target on IDEXX Laboratories shares from $603.00 to $573.00 and set an “overweight” rating on the stock in a Thursday, Aug. 4 report. Barclays cut its price target on IDEXX Laboratories shares from $700.00 to $582.00 and set an “overweight” rating on the stock in a Friday, August 5 report. Goldman Sachs Group upgraded IDEXX Laboratories shares from a “neutral” rating to a “buy” rating and cut its price target for the stock from $530.00 to $435.00 in a report from the Thursday July 21. Piper Sandler cut her price target on IDEXX Laboratories shares from $500.00 to $420.00 in a Monday, August 8 report. To finish, StockNews.com cut IDEXX Laboratories shares from a “buy” to a “hold” rating in a Monday, July 25 research note. Three research analysts gave the stock a hold rating and six gave the stock a buy rating. According to data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $483.57.
IDEXX Labs Price Performance
Shares of NASDAQ IDXX opened at $373.74 on Monday. The stock has a market capitalization of $31.12 billion, a price/earnings ratio of 48.22, a PEG ratio of 4.98 and a beta of 1.14. IDEXX Laboratories, Inc. has a 12-month low of $318.50 and a 12-month high of $695.18. The company’s 50-day simple moving average is $371.69 and its 200-day simple moving average is $434.61. The company has a debt ratio of 1.68, a current ratio of 0.89 and a quick ratio of 0.61.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and services primarily for the companion animal, livestock and poultry veterinary, dairy and water testing markets worldwide. The company operates through CAG; water quality products; LPD; and Other Segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables and rapid assay test kits; diagnostic and consultation services of a veterinary reference laboratory; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for the biomedical research community.
Read more
Want to see which other hedge funds hold IDXX? Visit HoldingsChannel.com for the latest 13F filings and insider trading for IDEXX Laboratories, Inc. (NASDAQ: IDXX – Get a rating).
Receive daily IDEXX lab news and reviews – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for IDEXX Laboratories and related companies with MarketBeat.com’s FREE daily newsletter.